Navigation Links
A New Approach In Treatment Neurogenic Detrusor Overactivity In Children

Many reports have dealt with the outcome of botulinum-a toxin (BTX-A) detrusor injections in patients with neurogenic or nonneurogenic detrusor overactivity. BTX-A detrusor injections have been described in adult// patients with neurogenic detrusor overactivity due to spinal cord injury.

Researchers from Germany were able to carry out the same experiments successfully in children with a neurogenic bladder. After many reports of this “wonder drug,” several questions have arisen, including what this injection treatment means for neurourologic patients in the longer term; whether bladder function changes after repeated BTX-A injections, and whether this procedure has a proper place in the treatment algorithm of young patients with neurogenic bladder. In an extension of their previous studies, the authors, set out o assess the long-term success of treatment with repeated botulinum-A toxin (BTX-A; Botox) injections into the detrusor muscle for neurogenic detrusor overactivity in children.

In their study published in the October issue of Urology, the researchers reviewed the charts of 10 children (average age at first injection 11.2 years) with neurogenic detrusor overactivity who had received at least three BTX-A detrusor injections; four had received five or more injections. The total dose of BTX-A was 85 to 300 U. They measured the urodynamic outcomes 6 months after each injection and compared the results after the first injection with the results after the third and fifth injections (in the children who had five or more injections).

The relative changes - each in comparison with the value before injection therapy - after the first versus the fifth injection were as follows: the reflex volume increased by 81% versus 88%, maximal detrusor pressure decreased by 7% versus 39%, maximal cystometric bladder capacity increased by 88% versus 72%, and bladder compliance showed no change at the 6-month follow-up visit after the first injection a nd an increase of 109% after the fifth injection. The results after the third injection were generally similar to those after the fifth injection. No major side effects occurred.

Patients with difficult bladder conditions refractory to anticholinergic drugs have traditionally undergone immediate surgical procedures, such as bladder augmentation. However, according to this new study, BTX-A detrusor injection offers a reliable alternative and protects some of those difficult-to-treat patients for years.
'"/>




Related medicine news :

1. New Dietary Approach To Manage Kidney Stones
2. Approaching through Telemedicine benefits patients
3. Gel Offers A More Targeted Approach
4. New Cost Effective Approach To Promote Sun Protection
5. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
6. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
7. Lazy Eye Can Be Effectively Treated By New Approach
8. Novel Approach to Identify Protein Links with Genetic Disorder
9. NHS To Be Reformed By Using A Hybrid Approach
10. Two-In One Approach To Prevent Incontinence After Prolapse Surgery
11. Women Afflicted With Dry Eyes As They Approach Menopause
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... McKinney, Texas (PRWEB) , ... March 23, 2017 ... ... Operations Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s ... Thomas. During the presentation, General Thomas thanked Task Force Dagger Foundation for its ...
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... an innovative patient - centric payment system, to expand its focus on patient ... the patient financial experience. , “At Ogden Clinic, we are working to ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... Pennsylvania , 22. März 2017 /PRNewswire/ ... unabhängige und weltweit tätige Anbieter von Produkten ... heute den Erwerb von EPL Archives Inc. ... Stoffe, der Kunden im kompletten Zyklus regulierter ... Verwahrung von Proben, Speicherung von Dokumenten und ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
Breaking Medicine Technology: